Skip to main content

Table 2 Yearly vaccination status according to age group and type of pneumococcal vaccine received during 2010 ~ 2015

From: The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia

 

Pneumococcal pneumonia cases by year

2010 (n = 179)

2011 (n = 329)

2012 (n = 273)

2013 (n = 81)

2014 (n = 82)

2015 (n = 39)

Total (n = 983)

Cases with any pneumococcal vaccination according to age

45 (25.1)

125 (38.0)

114 (41.8)

45 (55.6)

66 (80.5)

26 (66.7)

421/983 (42.8)

 < 2 years

5/26 (19.2)

9/33 (27.3)

9/23 (39.1)

3/9 (33.3)

13/18 (72.2)

3/3 (100)

42/112 (37.5)

 2-5 years

27/78 (34.6)

78/152 (51.3)

55/90 (61.1)

26/30 (86.7)

39/44 (88.6)

15/16 (93.8)

240/410 (65.9)

 5-18 years

13/75 (17.3)

38/144 (26.3)

50/160 (31.3)

16/42 (38.1)

14/20 (70.0)

8/20 (40.0)

139/461 (30.2)

Type of pneumococcal vaccine received

 PCV7

43/45 (95.6)

116/125 (92.8)

104/114 (91.2)

32/45 (71.1)

21/66 (31.8)

0/26 (0.0)

316/983 (32.2)

 PCV10

0 (0.0)

3/125 (2.4)

2/114 (1.75)

3/45 (6.7)

4/66 (6.1)

3/26 (11.5)

15/983 (1.5)

 PCV13

1/45 (2.2)

2/125 (1.6)

15/114 (13.2)

22/45 (48.9)

54/66 (81.8)

26/26 (100.0)

120/983 (12.2)

 PPV23

1/45 (2.22)

5/125 (4.0)

1/114 (0.9)

0/45 (0.0)

1/66 (1.5)

0/26 (0.0)

8/983 (0.8)

  1. Data are shown as n/N (%)
  2. PCV7, 7-valent polysaccharide conjugate vaccine; PCV10, 10-valent polysaccharide conjugate vaccine; PCV13, 13-valent polysaccharide conjugate vaccine; PPV23, 23-valent polysaccharide pneumococcal vaccine